Gabapentin — research review 1

...and this particular molecule, gabapentin, is fascinating because it’s not just a drug; it represents a pathway, specifically targeting alpha-2-delta calcium channels. These are crucial in how we experience pain, particularly neuropathic pain.

Right. And the link to aging and all-cause mortality here isn't that gabapentin itself causes death, but rather how chronic, unrelieved pain, often managed through this system, accelerates biological aging.

Exactly. We see evidence, for example, that "painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy." That was published in GeroScience in 2025. It suggests chronic pain isn't just unpleasant; it's a driver of biological wear and tear.

So, the chronic inflammation and stress from persistent pain, mediated in part through these pathways, seems to impact the epigenetic clock, effectively speeding up our biological age. It’s a mechanism where pain can genuinely shorten healthy lifespan.

But it's also important to discuss the drugs that act on this target, like gabapentin itself. While they can provide crucial relief for some, especially those with severe neuropathic pain, their long-term use isn't without considerations.

Absolutely. The risks of these medications, including side effects and potential for misuse, become part of the overall mortality picture. It’s a balancing act: addressing chronic pain that accelerates aging versus the potential harms of the intervention. What we still don't fully understand is the direct, long-term impact of modulating these channels on overall aging independent of pain relief.

Yes, the direct connection between blocking these channels and decelerated aging is largely unproven. The current evidence mostly points to unrelieved pain being the accelerant, and then the drugs as a separate risk factor.